Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis.

Antineoplastic Combined Chemotherapy Protocols / therapeutic use Biliary Tract Neoplasms / drug therapy Humans Neoplasm Recurrence, Local / drug therapy Prognosis Prospective Studies Retrospective Studies Treatment Outcome
Advanced biliary tract neoplasms ampullary neoplasms chemotherapy extrahepatic cholangiocarcinoma gallbladder neoplasms intrahepatic cholangiocarcinoma prognosis

Journal

Journal of chemotherapy (Florence, Italy)
ISSN: 1973-9478
Titre abrégé: J Chemother
Pays: England
ID NLM: 8907348

Informations de publication

Date de publication:
Apr 2022
Historique:
pubmed: 28 7 2021
medline: 25 3 2022
entrez: 27 7 2021
Statut: ppublish

Résumé

Advanced biliary tract cancer (aBTC) comprises a heterogeneous group of rare malignancies with dismal prognosis. Given the scarcity of prospective evidence, the aim of this study was to derive clinically useful insights and prognostic factors from a large, real-world series of aBTC. Clinicopathologic variables and treatment outcomes were retrospectively collected involving 940 patients diagnosed with aBTC between 2001 and 2017, and treated with first-line chemotherapy (CT1) at 14 Italian medical oncology institutions. Median overall survival (OS) was 10.3 months (CI

Identifiants

DOI: 10.1080/1120009X.2021.1953887 PMID: 34313188
pubmed: 34313188
doi: 10.1080/1120009X.2021.1953887
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123-132

Auteurs

Roberto Filippi (R)

Department of Oncology, University of Turin, Torino, Italy.
Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Italy.
Division of Medical Oncology 1, Centro Oncologico Ematologico Subalpino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

Francesco Leone (F)

Division of Medical Oncology, ASL BI, Nuovo Ospedale degli Infermi, Ponderano, Italy.

Lorenzo Fornaro (L)

Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

Giuseppe Aprile (G)

Department of Oncology, University Hospital of Udine, Udine, Italy.
Department of Oncology, San Bortolo General Hospital, Vicenza, Italy.

Andrea Casadei-Gardini (A)

Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Department of Oncology and Haematology, University Hospital of Modena, Italy.

Nicola Silvestris (N)

Medical Oncology Unit, IRCCS Cancer Institute "Giovanni Paolo II", Bari, Italy.

Andrea Palloni (A)

Department of Experimental, Diagnostic and Speciality Medicine, University Hospital S. Orsola-Malpighi, Bologna, Italy.

Maria Antonietta Satolli (MA)

Department of Oncology, University of Turin, Torino, Italy.
Division of Medical Oncology 1, Centro Oncologico Ematologico Subalpino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

Mario Scartozzi (M)

Department of Medical Oncology, University Hospital, Cagliari, Italy.

Marco Russano (M)

Department of Medical Oncology, Campus Bio-Medico University, Roma, Italy.

Stefania Eufemia Lutrino (SE)

Department of Oncology, Ospedale Vito Fazzi, Lecce, Italy.

Pasquale Lombardi (P)

Department of Oncology, University of Turin, Torino, Italy.
Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Italy.

Giorgio Frega (G)

Department of Experimental, Diagnostic and Speciality Medicine, University Hospital S. Orsola-Malpighi, Bologna, Italy.

Silvio Ken Garattini (SK)

Department of Oncology, University Hospital of Udine, Udine, Italy.

Caterina Vivaldi (C)

Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy.

Rosella Spadi (R)

Division of Medical Oncology 1, Centro Oncologico Ematologico Subalpino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

Orsi Giulia (O)

Department of Oncology and Haematology, University Hospital of Modena, Italy.

Elisabetta Fenocchio (E)

Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.

Oronzo Brunetti (O)

Medical Oncology Unit, IRCCS Cancer Institute "Giovanni Paolo II", Bari, Italy.

Massimo Aglietta (M)

Department of Oncology, University of Turin, Torino, Italy.
Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Italy.

Giovanni Brandi (G)

Department of Experimental, Diagnostic and Speciality Medicine, University Hospital S. Orsola-Malpighi, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Clinical insights and prognostic factors from...
questionsmedicales.fr › Maladies de l'appareil digestif › Tumeurs de l'appareil digestif › Tumeurs des voies biliaires › Clinical insights and prognostic factors from...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Clinical insights and prognostic factors from...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Clinical insights and prognostic factors from...
questionsmedicales.fr › Diagnostic › Pronostic › Clinical insights and prognostic factors from...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Clinical insights and prognostic factors from...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Clinical insights and prognostic factors from...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Clinical insights and prognostic factors from...